Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002

Purpose of reviewThe present review assesses recent publications, from 2001 until the present, which address the relationship between cardiovascular disease (CVD) and anaemia in patients with chronic kidney disease. Recent findingsInsights from the recently published basic science literature have helped to place findings from clinical studies into a new context, and thereby assist us to understand and further explore the complex relationship between haemoglobin level and survival in chronic kidney disease. The effects of erythropoietin molecules and the presence of receptors in vascular endothelium, mycoardium and other tissues are described. Both observational and interventional clinical studies are examined, and limitations in the methodology and statistical analysis of clinical studies are emphasized, but are given context within the body of literature preceding the past year's publications. SummaryData suggest that development of CVD in patients with kidney disease is multifactorial. Several factors associated with CVD are also associated with anaemia, thereby making causal arguments for the role of anaemia in CVD and survival difficult. Arguments are made for the importance of prevention of anaemia and of individualizing therapeutic goals for its treatment. Well designed prospective studies with both CVD events and mortality as outcomes, and with enrolment beginning before the start of dialysis, are essential if we are to determine the optimal therapeutic strategies.

[1]  I. Macdougall,et al.  PRE-dialysis survey on anaemia management. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  C. Zoccali,et al.  Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. , 2002, Journal of the American Society of Nephrology : JASN.

[3]  J. Griffith,et al.  Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. , 2002, Journal of the American College of Cardiology.

[4]  B. Astor,et al.  Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). , 2002, Archives of internal medicine.

[5]  A. Levin,et al.  The relationship of haemoglobin level and survival: direct or indirect effects? , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  R. Foley,et al.  Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. , 2002, Journal of the American Society of Nephrology : JASN.

[7]  L. Stevens,et al.  Should Hemoglobin be Normalized in Patients with Chronic Kidney Disease? , 2002, Seminars in dialysis.

[8]  N. Ahsan,et al.  Editorials: Dialysis Access Failure: An Indication for Immediate Kidney Transplantation , 2002, Seminars in dialysis.

[9]  S. Klarenbach,et al.  Reduced Requirement for Erythropoietin with Quotidian Hemodialysis Therapy , 2002, ASAIO journal.

[10]  M. Rocco,et al.  Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  S. Kihara,et al.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[12]  B. Lindholm,et al.  Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. , 2002, Journal of the American Society of Nephrology : JASN.

[13]  P. Vallance Importance of asymmetrical dimethylarginine in cardiovascular risk , 2001, The Lancet.

[14]  C. Zoccali,et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.

[15]  P. Fein,et al.  Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  J. Blacher,et al.  Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. , 2001, Journal of the American Society of Nephrology.

[17]  A. Collins,et al.  Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. , 2001, Journal of the American Society of Nephrology : JASN.

[18]  A. Kausz,et al.  Anemia: an early complication of chronic renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  K. Eckardt Anaemia in end-stage renal disease: pathophysiological considerations. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  K. Eckardt After 15 years of success--perspectives of erythropoietin therapy. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  M. Kikuchi,et al.  Five‐Year Survival of Older People with Anemia: Variation with Hemoglobin Concentration , 2001, Journal of the American Geriatrics Society.

[22]  A. Cerami,et al.  Beyond erythropoiesis: novel applications for recombinant human erythropoietin. , 2001, Seminars in hematology.

[23]  G. Stabellini,et al.  Erythropoietin and Cardiocirculatory Condition in Aged Patients with Chronic Rena l Failure , 2001, Nephron.

[24]  I. Shapira,et al.  The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.

[25]  G. Thomas The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. , 2001, Seminars in oncology.

[26]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Blacher,et al.  Impact of Aortic Stiffness Attenuation on Survival of Patients in End-Stage Renal Failure , 2001, Circulation.

[28]  J. Fink,et al.  Use of erythropoietin before the initiation of dialysis and its impact on mortality. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  B Fellström,et al.  Impaired endothelium-dependent vasodilatation in renal failure in humans. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  R. Brant,et al.  Poor long-term survival after coronary angiography in patients with renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  C. Zoccali,et al.  Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  M. Gassmann,et al.  Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Yee,et al.  Risks associated with renal dysfunction in patients in the coronary care unit. , 2000, Journal of the American College of Cardiology.

[35]  A. Levin,et al.  Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. , 2000, Kidney international.

[36]  Mohamed,et al.  Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. , 2000, Kidney international.

[37]  O. Sommerburg,et al.  Oxidation parameters in complete correction of renal anemia. , 2000, Clinical nephrology.

[38]  Avid,et al.  THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .

[39]  G. Remuzzi,et al.  Physiology and pathophysiology of nitric oxide in chronic renal disease. , 1999, Proceedings of the Association of American Physicians.

[40]  M. Iruela-Arispe,et al.  Inactivation of erythropoietin leads to defects in cardiac morphogenesis. , 1999, Development.

[41]  J. Singer,et al.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  E. Ritz,et al.  Myocyte/capillary mismatch in the heart of uremic patients. , 1998, Journal of the American Society of Nephrology : JASN.

[43]  E. Morishita,et al.  In vivo evidence that erythropoietin protects neurons from ischemic damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  W. Owen,et al.  Anemia in hemodialysis patients: variables affecting this outcome predictor. , 1997, Journal of the American Society of Nephrology : JASN.

[45]  David C. Murray,et al.  The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  E. Borda,et al.  Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: Signal transduction pathways , 1996, Journal of cellular physiology.

[47]  J. Singer,et al.  Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  W. Curran,et al.  Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  David C. Murray,et al.  Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. , 1995, Kidney international.

[50]  E. Borda,et al.  Erythropoietin modified the cardiac action of ouabain in chronically anaemic-uraemic rats. , 1995, Nephron.

[51]  David C. Murray,et al.  Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. , 1995, Kidney international.

[52]  P. Parfrey,et al.  Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. , 1994, Journal of the American Society of Nephrology : JASN.

[53]  E. Ritz,et al.  Reduced capillary density in the myocardium of uremic rats--a stereological study. , 1992, Kidney international.

[54]  A. Raine,et al.  Effects of oxygen breathing and erythropoietin on hypoxic vasodilation in uremic anemia. , 1992, Kidney international.

[55]  M. Safar,et al.  Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. , 1989, Kidney international.